高级检索
中华肿瘤杂志
期刊首页
过刊列表
高级检索
稿件发表
• 临床应用 •
ENGLISH ABSTRACT
吉西他滨联合奈达铂治疗人表皮生长因子受体2阴性晚期乳腺癌的疗效和安全性
岳健
胡南林
王雪
司怡然
高崧淋
郑方超
巨洁
袁芃
作者及单位信息
·
DOI： 10.3760/cma.j.cn112152-20200809-00723
Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer
Yue Jian
Hu Nanlin
Wang Xue
Si Yiran
Gao Songlin
Zheng Fangchao
Ju Jie
Yuan Peng
Authors Info & Affiliations
Yue Jian
Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Hu Nanlin
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Wang Xue
Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Si Yiran
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Gao Songlin
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Zheng Fangchao
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Ju Jie
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yuan Peng
Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
·
DOI： 10.3760/cma.j.cn112152-20200809-00723
620
32
0
0
4
0
PDF下载
APP内阅读
摘要

目的评估吉西他滨联合奈达铂(GN方案)治疗人表皮生长因子受体2(HER-2)阴性晚期乳腺癌的疗效及安全性。

方法选择既往接受过蒽环类和(或)紫杉类药物辅助或新辅助治疗的HER-2阴性复发转移性乳腺癌患者45例，2014年1月至2019年2月在中国医学科学院肿瘤医院接受GN方案治疗。根据实体瘤的疗效评价标准(RECIST)1.1进行疗效评价，根据通用不良事件评价标准(CTCAE)进行不良反应的评估和监测。随访患者的无进展生存时间(PFS)和总生存时间(OS)，分析预后影响因素。

结果45例患者接受中位4个周期的治疗，其中1例完全缓解，21例部分缓解，客观缓解率为48.9%(95% CI: 33.7%～64.1%)。10例(22.2%)患者出现3～4级白细胞减少，13例(28.9%)出现3～4级中性粒细胞减少，8例(17.8%)出现3～4级血小板减少。3～4级非血液学不良反应主要为恶心呕吐，发生率为4.4%(2/45)。45例患者中，34例死亡，中位PFS为5.1个月(95% CI: 3.9～6.1个月)，中位OS为17.6个月(95% CI: 13.1～20.9个月)。

结论对于既往接受过蒽环类和(或)紫杉类药物治疗的HER-2阴性复发转移性晚期乳腺癌患者，GN方案是一种有效且耐受性较好的化疗方案。

乳腺肿瘤;吉西他滨;奈达铂;人表皮生长因子受体2
ABSTRACT

ObjectiveTo assess the therapeutic efficacy and safety of the gemcitabine combined with nedaplatin (GN) chemotherapy for metastatic human epidermal growth factor receptor-2 (HER-2) negative breast cancer patients.

MethodsForty-five patients with HER-2 negative recurrent metastatic breast cancer who had received prior adjuvant or neoadjuvant therapy with anthracycline and/or taxanes were enrolled. All the patients received GN regime from January 2014 to February 2019. The therapeutic efficacy was evaluated according to response evaluation criteria in solid tumors (RECIST) 1.1. The adverse response was evaluated and monitored according to common terminology criteria for adverse events (CTCAE). The progression-free survival (PFS) and overall survival (OS) and prognostic factors were also analyzed.

ResultsAll of the 45 patients received 4 course GN, 1 of them achieved complete response, 21 achieved partial response. The objective response rate was 48.9 (95% CI: 33.7%-64.1%). Grade 3-4 hematological toxicities include leukopenia occurred in 10 (22.2%) of patients, neutropenia in 13 (28.9%) patients, and thrombocytopenia in 8 (17.6%) patients. The grade 3-4 hematological toxicities mainly manifested as nausea and vomiting, and the incidence was 4.4% (2/45). Among the 45 patients, 34 died, the median PFS was 5.1 (95% CI: 3.9-6.1) months and the median OS was 17.6 (95% CI: 13.1-20.9) months.

ConclusionThe combination of gemcitabine and nedaplatin is an effective and tolerable treatment for metastatic breast cancer patients previously treated with anthracyclines and/or taxanes.

Breast neoplasms;Gemcitabine;Nedaplatin;Human epidermal growth factor receptor-2
Yuan Peng, Email: mocdef.labiamtoh10gnepnauy
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

岳健,胡南林,王雪,等. 吉西他滨联合奈达铂治疗人表皮生长因子受体2阴性晚期乳腺癌的疗效和安全性[J]. 中华肿瘤杂志,2021,43(08)：883-888.

DOI:10.3760/cma.j.cn112152-20200809-00723

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

在复发转移性晚期乳腺癌的治疗过程中，对治疗药物的耐药性是影响治疗的主要因素。对于复发转移性乳腺癌治疗的新化疗方案，要求在克服耐药、延长生存时间的同时，应有较为良好的耐受性。吉西他滨作为一种新型的嘧啶类抗代谢药物，广泛应用于恶性肿瘤治疗中 [ 1 ]，与铂类药物具有协同作用 [ 2 ]。吉西他滨联合顺铂方案治疗晚期肺癌的有效率为28%～54%，中位生存时间为7.6～15.4个月，1年生存率为35%～61% [ 3 , 4 ]。吉西他滨联合卡铂治疗晚期恶性肿瘤有效率约为25%～52%，中位生存时间为7.4～15.4个月 [ 5 , 6 , 7 , 8 , 9 ]。奈达铂为第2代铂类药物，其治疗机制与顺铂相似，主要通过阻断DNA修复发挥抗肿瘤作用 [ 4 , 10 ]。研究表明，奈达铂具有与顺铂同等或比顺铂更高的抗肿瘤活性，且肾毒性更小，其剂量限制性毒性为中性粒细胞和血小板减少 [ 2 ]。鉴于目前尚无吉西他滨联合奈达铂治疗复发转移性乳腺癌的相关数据，在本研究中，我们采用这一方案治疗了45例人表皮生长因子受体2(human epidermal growth factor receptor-2, HER-2)阴性复发转移性乳腺癌患者，前瞻性观察了其疗效和安全性。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
de Sousa Cavalcante L , Monteiro G . Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer[J]. Eur J Pharmacol, 2014,741：8-16. DOI: 10.1016/j.ejphar.2014.07.041 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Matsumoto M , Takeda Y , Maki H ,et al. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer[J]. Jpn J Cancer Res, 2001,92(1)：51-58. DOI: 10.1111/j.1349-7006.2001.tb01047.x .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Sandler A , Ettinger DS . Gemcitabine: single-agent and combination therapy in non-small cell lung cancer[J]. Oncologist, 1999,4(3)：241-251.
返回引文位置Google Scholar
百度学术
万方数据
[4]
Hirose T , Horichi N , Ohmori T ,et al. Phase Ⅰ study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer[J]. Lung Cancer, 2003,39(1)：91-97. DOI: 10.1016/s0169-5002(02)00305-7 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Kosmidis PA , Kalofonos HP , Christodoulou C ,et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase Ⅲ study of the Hellenic Cooperative Oncology Group[J]. Ann Oncol, 2008,19(1)：115-122. DOI: 10.1093/annonc/mdm430 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Genestreti G , Giovannini N , Frizziero M ,et al. Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study[J]. J Chemother, 2011,23(4)：232-237. DOI: 10.1179/joc.2011.23.4.232 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Lee SM , James LE , Qian W ,et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer[J]. Thorax, 2009,64(1)：75-80. DOI: 10.1136/thx.2007.093872 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Yang JJ , Zhou Q , Liao RQ ,et al. Nedaplatin/gemcitabine versus carboplatin/gemcitabine in treatment of advanced non-small cell lung cancer: a randomized clinical trial[J]. Chin J Cancer Res, 2012,24(2)：97-102. DOI: 10.1007/s11670-012-0097-8 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Park JH , Lee SW , Kim HS ,et al. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract[J]. Cancer Chemother Pharmacol, 2013,71(4)：1033-1039. DOI: 10.1007/s00280-013-2098-9 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Sekine I , Nokihara H , Horiike A ,et al. Phase Ⅰ study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma[J]. Br J Cancer, 2004,90(6)：1125-1128. DOI: 10.1038/sj.bjc.6601700 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Rosati G , Riccardi F , Tucci A ,et al. A phase Ⅱ study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy[J]. Tumori, 2000,86(3)：207-210.
返回引文位置Google Scholar
百度学术
万方数据
[12]
Zhang J , Wang Z , Hu X ,et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer[J]. Int J Cancer, 2015,136(1)：204-211. DOI: 10.1002/ijc.28966 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Chew HK , Doroshow JH , Frankel P ,et al. Phase Ⅱ studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer[J]. J Clin Oncol, 2009,27(13)：2163-2169. DOI: 10.1200/JCO.2008.17.4839 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Isakoff SJ , Mayer EL , He L ,et al. TBCRC009: a multicenter phase Ⅱ clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015,33(17)：1902-1909. DOI: 10.1200/JCO.2014.57.6660 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Hu XC , Zhang J , Xu BH ,et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015,16(4)：436-446. DOI: 10.1016/S1470-2045(15)70064-1 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Zhang J , Lin Y , Sun XJ ,et al. Biomarker assessment of the CBCSG006 trial: a randomized phase Ⅲ trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2018,29(8)：1741-1747. DOI： 10.1093/annonc/mdy209747 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Li Q , Li Q , Zhang P ,et al. A phase Ⅱ study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes[J]. Cancer Biol Ther, 2015,16(12)：1746-1753. DOI: 10.1080/15384047.2015.1095400 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Yao G , Cao L , Liu M ,et al. Gemcitabine and capecitabine combination chemotherapy in patients with metastatic breast cancer pretreated with anthracyclines and/or taxanes. Chemotherapy, 2016,61(4)：171-178. DOI: 10.1159/000443366 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Pang H , Feng T , Lu H ,et al. Efficacy and safety of nedaplatin in advanced breast cancer therapy[J]. Cancer Invest, 2016,34(4)：167-172. DOI: 10.3109/07357907.2016.1144061 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Yuan P , Hu X , Sun T ,et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial[J]. Eur J Cancer, 2019,112：57-65. DOI: 10.1016/j.ejca.2019.02.002 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Sugiyama T , Hirose T , Nakashima M ,et al. Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer[J]. Oncology, 2011,81(3-4)：273-280. DOI: 10.1159/000334430 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Matsumoto K , Mochizuki K , Hirayama T ,et al. Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy[J]. Asian Pac J Cancer Prev, 2015,16(6)：2483-2487. DOI: 10.7314/apjcp.2015.16.6.2483 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Shirai T , Hirose T , Noda M ,et al. Phase Ⅱ study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer[J]. Lung Cancer, 2006,52(2)：181-187. DOI: 10.1016/j.lungcan.2006.01.004 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
袁芃，Email： mocdef.labiamtoh10gnepnauy
B
所有作者均声明不存在利益冲突
C
中国癌症基金会北京希望马拉松专项基金 (LC2018B15)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
曲妥珠单抗联合多西他赛治疗人表皮生长因子受体2阳性晚期乳腺癌的效果及安全性
王仙玲 等
肿瘤研究与临床 2024,36(12)
中医药联合阿贝西利及内分泌药物治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的安全性分析
赵依庞 等
国际中医中药杂志 2024,46(07)
艾立布林治疗晚期乳腺癌疗效和安全性的多中心真实世界研究
桑蝶 等
中华肿瘤杂志 2022,44(04)
吉西他滨联合替吉奥治疗晚期胰腺癌的疗效和安全性
江英强 等
中华肿瘤杂志 2015,37(06)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大